iRhythm (IRTC) Stock Sees Modest Fair Value Cut After VitalConnect And Zio MCT Questions

Price target updates for iRhythm Holdings now reflect a slightly lower fair value of US$171.33 compared with the prior US$178.93. Analysts link this adjustment to fresh views on execution risk around the VitalConnect acquisition, the timing of Zio MCT, and a wider spread between optimistic and cautious expectations after Q2. As you read on, you will see how these evolving targets help you track the shifting narrative around iRhythm Holdings and what to watch next.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value iRhythm Holdings.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Piper Sandler and Stephens both started coverage of iRhythm with Overweight ratings and US$160 price targets, pointing to the company's position in long term continuous cardiac monitoring and the potential of Zio MCT and VitalPatch in mobile cardiac telemetry.

• Canaccord lifted its iRhythm price target to US$196 from US$157 after Q2 results and the VitalConnect deal, citing updated guidance that includes management's revenue projection of US$880m to US$890m for FY26.

• Truist, Baird, and Wells Fargo each set targets in the US$150 to US$196 range following Q2 and the VitalConnect acquisition. They see this as expanding iRhythm's reach in remote monitoring while still keeping an Overweight, Buy, or Outperform stance.

🐻 Bearish Takeaways

• Piper Sandler highlights that iRhythm shares are down year to date, with investors focused on implied slower growth in the second half of 2026 and concerns around the timing and impact of Zio MCT.

• Wells Fargo's cut to US$150 and earlier target trims from Wells Fargo and others reflect questions about VitalConnect execution and the possibility that VitalPatch could partially replace Zio AT and Zio MCT sales over time.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

We've flagged 1 risk for iRhythm Holdings. See which could impact your investment.

What's in the News

• iRhythm Holdings reported Q2 2026 results that management described as strong, with revenue up 20.1% year over year and demand supported by the Zio cardiac monitoring platform.

• The company disclosed a cybersecurity incident involving unauthorized access to third party hosted applications, which exposed certain patient personal and protected health information, and began notifying affected individuals by October 2026.

• Edelson Lechtzin LLP is investigating potential data privacy claims tied to the breach, while Halper Sadeh LLC is reviewing whether certain iRhythm officers and directors breached fiduciary duties to shareholders.

• A proposed US$45,000,000 securities class action settlement related to prior disclosures about the Zio AT heart monitoring device is moving toward a court hearing on November 5, 2026, in the Northern District of California.